Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.

Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O.

Pituitary. 2009;12(3):153-7. doi: 10.1007/s11102-008-0134-2.

PMID:
18594989
2.

Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.

Elenkova A, Shabani R, Kalinov K, Zacharieva S.

Eur J Endocrinol. 2012 Jul;167(1):17-25. doi: 10.1530/EJE-12-0121. Epub 2012 Apr 16.

3.

A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.

Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M.

Pituitary. 2012 Mar;15(1):44-9. doi: 10.1007/s11102-011-0339-7.

PMID:
21847572
4.

Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.

Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.

J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56. doi: 10.1210/jc.2007-2658. Epub 2008 Jun 17.

PMID:
18559921
5.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

6.

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.

Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA.

Clin Endocrinol (Oxf). 2009 Jan;70(1):104-8. doi: 10.1111/j.1365-2265.2008.03458.x.

PMID:
19128367
7.

Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?

Vallette S, Serri K, Serri O.

Expert Rev Cardiovasc Ther. 2010 Jan;8(1):49-54. doi: 10.1586/erc.09.167.

PMID:
20014934
8.

Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.

Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA, Klibanski A.

Clin Endocrinol (Oxf). 2010 Jan;72(1):53-8. doi: 10.1111/j.1365-2265.2009.03608.x. Epub 2009 Apr 17.

PMID:
19508591
9.

Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.

Kars M, Pereira AM, Bax JJ, Romijn JA.

Eur J Endocrinol. 2008 Oct;159(4):363-7. doi: 10.1530/EJE-08-0611. Epub 2008 Aug 14. Review.

10.

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.

Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A.

Eur J Endocrinol. 2013 Aug 28;169(3):359-66. doi: 10.1530/EJE-13-0231. Print 2013 Sep.

11.

[Cabergoline in hyperprolactinemia and valvular heart disease].

Vargas ML, Cervantes CE, Hernando CA, Da Costa CV.

Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1. Review. Spanish.

PMID:
19959151
12.

Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.

Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA, Holman ER, Feelders RA, Smit JW, Bax JJ, Pereira AM.

Clin Endocrinol (Oxf). 2012 Jul;77(1):99-105. doi: 10.1111/j.1365-2265.2011.04326.x.

PMID:
22211510
13.

Cabergoline and the risk of valvular lesions in endocrine disease.

Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A.

Eur J Endocrinol. 2008 Jul;159(1):1-5. doi: 10.1530/EJE-08-0213. Epub 2008 May 2.

14.

No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.

Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, Santos AE, Batista E, García-Pavía P, Sitges M, Mirelis JG, Lucas T, Puig-Domingo M.

Clin Endocrinol (Oxf). 2012 Aug;77(2):275-80. doi: 10.1111/j.1365-2265.2012.04349.x.

PMID:
22288503
15.

Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.

Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E.

Int J Clin Pract. 2008 Dec;62(12):1864-9. doi: 10.1111/j.1742-1241.2008.01779.x. Epub 2008 May 6.

PMID:
18462372
16.

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.

Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G.

J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84. doi: 10.1210/jc.2007-1403. Epub 2008 Aug 5.

PMID:
18682513
17.

Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.

Yarman S, Kurtulmus N, Bilge A.

Neuro Endocrinol Lett. 2012;33(3):340-6.

PMID:
22635095
18.

Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.

Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.

Clin Neurol Neurosurg. 2007 May;109(4):350-3. Epub 2007 Feb 20.

PMID:
17307289
19.

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Antonini A, Poewe W.

Lancet Neurol. 2007 Sep;6(9):826-9. Review.

PMID:
17706566
20.

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.

De Vecchis R, Esposito C, Ariano C.

Herz. 2013 Dec;38(8):868-80. doi: 10.1007/s00059-013-3816-0. Epub 2013 Jun 8. Review.

PMID:
23743769
Items per page

Supplemental Content

Write to the Help Desk